All Updates

All Updates

icon
Filter
Funding
Partnerships
PostEra raises USD 24 million Series A; secures USD 260 million AI deal with Pfizer
AI Drug Discovery
Jan 11, 2022
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Jan 11, 2022

PostEra raises USD 24 million Series A; secures USD 260 million AI deal with Pfizer

Funding
Partnerships

  • California-based AI drug discovery company PostEra has raised USD 24 million in a Series A funding round led by The Clermont Group, with participation from new investors Breyer Capital and Lifeforce Capital, and existing investors HOF Capital and Pioneer Fund, among others. 

  • The proceeds will be used to further develop its medicinal chemistry platform, establish its own drug discovery pipeline, and advance its collaborative drug discovery programs. 

<ul><li> Simultaneously, the company also extended its multi-year strategic partnership with Pfizer entered in December 2020 , to establish an AI lab. The lab will leverage Pfizer’s drug discovery expertise and data, together with PostEra’s AI technology, to work on a number of drug discovery programs across oncology and Covid-19.</ul>

  • As part of the renewed deal, PostEra will receive an upfront payment of USD 13 million, followed by up to USD 248 million in additional milestones and other tiered royalties.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.